Evidence map›Paper›PMID 41337046›Full record

ArticlePLoS computational biology2025

Natural variants of von Willebrand factor R1205 causing von Willebrand disease with accelerated von Willebrand factor clearance: In silico docking models and energetics of the interaction with both LRP1 and GpIb A1 domain.

Monica Sacco, Stefano Lancellotti, Antonietta Ferretti, Maria Basso, Leonardo Di Gennaro, Giancarlo Castaman, Raimondo De Cristofaro

Abstract read
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Monica SaccoDipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Facoltà di Medicina e Chirurgia "Agostino Gemelli", Roma, Italy.
Stefano LancellottiServizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemell" IRCCS, Roma, Italy.
Antonietta FerrettiServizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemell" IRCCS, Roma, Italy.ORCID 0000-0001-7115-8743
Maria BassoServizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemell" IRCCS, Roma, Italy.
Leonardo Di GennaroServizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemell" IRCCS, Roma, Italy.
Giancarlo CastamanCentro Malattie Emorragiche e della Coagulazione, Dipartimento di Oncologia, Ospedale Universitario "Careggi", Firenze, Italy.
Raimondo De CristofaroDipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Facoltà di Medicina e Chirurgia "Agostino Gemelli", Roma, Italy.ORCID 0000-0002-8066-8849

Funding

Catholic University of the Sacred Heart -School of Medicine- Rome
6 · The paper itself

Abstract

Type 1 von Willebrand disease (VWD) is often caused by variants in von Willebrand factor (VWF), including p.R1205H ("Vicenza mutation"), which accelerate VWF clearance via macrophage receptor LRP1 and impair platelet adhesion and activation. However, the structural mechanisms underlying these phenotypes remain partially unclear. Here, we use integrative computational modeling (I-TASSER, HADDOCK2.4, and PRODIGY) to predict how p.R1205H/C/L/S variants alter VWF interaction with LRP1 and its platelet receptor GPIbα that binds to the A1 VWF domain. Our models reveal that R1205 acts as a structural hinge: its variants disrupt polar networks in VWF's D3 domain, exposing neo-epitopes that enhance LRP1 binding (ΔΔG up to -5.3 kcal/mol) while destabilizing the A1 domain's α1-β2 loop, reducing GPIbα affinity (≅30-fold for R1205L/C). These findings explain clinical observations, p.R1205H rapid clearance yet retained platelet adhesion, and establish R1205 as a dual-functional switch regulating VWF circulatory lifetime and hemostatic activity. This analytical procedure provides a template for predicting pathogenicity of VWF variants and designing targeted therapies for VWD.

Indexed as

Low Density Lipoprotein Receptor-Related Protein-1Platelet Glycoprotein GPIb-IX Complexvon Willebrand Diseasesvon Willebrand FactorComputational BiologyHumansMolecular Docking SimulationMutationProtein BindingProtein Domainsadhesion receptorLow Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanPlatelet Glycoprotein GPIb-IX Complexvon Willebrand Factor

Identifiers

PMID41337046
PMCPMC12711066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.